NVRO Quote, Financials, Valuation and Earnings

Inspire Medical Systems has a net margin of -15.83% compared to Nevro's net margin of 9.1%. Nevro's return on equity of -24.66% beat Inspire Medical Systems's return on equity of 5.44%.

Nevro has a consensus price target of $5.68, signalling upside risk potential of 49.96%. On the other hand Inspire Medical Systems has an analysts' consensus of $239.60 which suggests that it could grow by 27.6%. Given that Nevro has higher upside potential than Inspire Medical Systems, analysts believe Nevro is more attractive than Inspire Medical Systems.

Nevro has a beta of 0.841, which suggesting that the stock is 15.88% less volatile than S&P 500. In comparison Inspire Medical Systems has a beta of 1.313, suggesting its more volatile than the S&P 500 by 31.289%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Inspire Medical Systems pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $96.9M, which are smaller than Inspire Medical Systems quarterly revenues of $203.2M. Nevro's net income of -$15.3M is lower than Inspire Medical Systems's net income of $18.5M. Notably, Nevro's price-to-earnings ratio is -- while Inspire Medical Systems's PE ratio is 175.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.33x versus 7.47x for Inspire Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -15.83% compared to Nevro's net margin of -10.5%. Nevro's return on equity of -24.66% beat Myomo's return on equity of -84.04%.

Nevro has a consensus price target of $5.68, signalling upside risk potential of 49.96%. On the other hand Myomo has an analysts' consensus of $7.04 which suggests that it could grow by 25.27%. Given that Nevro has higher upside potential than Myomo, analysts believe Nevro is more attractive than Myomo.

Nevro has a beta of 0.841, which suggesting that the stock is 15.88% less volatile than S&P 500. In comparison Myomo has a beta of 1.709, suggesting its more volatile than the S&P 500 by 70.858%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $96.9M, which are larger than Myomo quarterly revenues of $9.2M. Nevro's net income of -$15.3M is lower than Myomo's net income of -$966.4K. Notably, Nevro's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.33x versus 8.94x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of -15.83% compared to Nevro's net margin of -11.97%. Nevro's return on equity of -24.66% beat Inari Medical's return on equity of -17.68%.

Nevro has a consensus price target of $5.68, signalling upside risk potential of 49.96%. On the other hand Inari Medical has an analysts' consensus of $66.46 which suggests that it could grow by 19.79%. Given that Nevro has higher upside potential than Inari Medical, analysts believe Nevro is more attractive than Inari Medical.

Nevro has a beta of 0.841, which suggesting that the stock is 15.88% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $96.9M, which are smaller than Inari Medical quarterly revenues of $153.4M. Nevro's net income of -$15.3M is higher than Inari Medical's net income of -$18.4M. Notably, Nevro's price-to-earnings ratio is -- while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.33x versus 5.60x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -15.83% compared to Nevro's net margin of -67.31%. Nevro's return on equity of -24.66% beat Stereotaxis's return on equity of -108.68%.

Nevro has a consensus price target of $5.68, signalling upside risk potential of 49.96%. On the other hand Stereotaxis has an analysts' consensus of -- which suggests that it could grow by 91.49%. Given that Stereotaxis has higher upside potential than Nevro, analysts believe Stereotaxis is more attractive than Nevro.

Nevro has a beta of 0.841, which suggesting that the stock is 15.88% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.570, suggesting its more volatile than the S&P 500 by 57.046%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $96.9M, which are larger than Stereotaxis quarterly revenues of $9.2M. Nevro's net income of -$15.3M is lower than Stereotaxis's net income of -$6.2M. Notably, Nevro's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.33x versus 7.87x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.